Published in Adv Biochem Psychopharmacol on January 01, 1974
Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase. J Pharmacol Exp Ther (1968) 1.54
In vivo enhancement of tyrosine hydroxylation in rat striatum by tetrahydrobiopterin. Nature (1974) 1.51
Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Engl J Med (1981) 1.48
Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature (1967) 1.44
Enhancement of noradrenaline turnover in rat brain by L-dopa. J Pharm Pharmacol (1974) 1.43
Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxyphenylalanine. J Pharm Pharmacol (1969) 1.35
The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther (1975) 1.28
Upregulation of gamma-aminobutyric acid (GABA) B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock. J Pharmacol Exp Ther (1985) 1.20
Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther (1986) 1.19
3-O-methyldopa, a new precursor of dopamine. Nature (1971) 1.17
Two types of 5-hydroxytryptamine release from isolated blood platelets. Experientia (1964) 1.17
Decarboxylase inhibitors. Pharmacol Ther B (1975) 1.15
Metabolic fate of l-[14C] DOPA in cerebrospinal fluid and blood plasma of humans. Brain Res (1967) 1.14
Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase. J Pharm Pharmacol (1968) 1.14
Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties. J Pharmacol Exp Ther (1988) 1.10
Atropine-induced changes of cerebral dopamine turnover. Experientia (1971) 1.09
Alterations of GABA-mediated synaptic transmission in human epilepsy. Adv Neurol (1986) 1.08
The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin Pharmacol Ther (1971) 1.06
L-dopa-induced accumulation of 3-O-metyldopa in brain and heart. Eur J Pharmacol (1970) 1.03
Quinolinic-phosphoribosyl transferase activity is decreased in epileptic human brain tissue. Epilepsia (1988) 1.01
Dissociation between biochemical and ultrastructural effects of 6-hydroxydopamine in rat brain. Experientia (1970) 1.01
Ifenprodil and SL 82.0715 as cerebral antiischemic agents. III. Evidence for antagonistic effects at the polyamine modulatory site within the N-methyl-D-aspartate receptor complex. J Pharmacol Exp Ther (1990) 1.01
Temperature sensitivity of the passive outflow of 5-hydroxytryptamine from blood platelets. Life Sci (1965) 0.98
Sulphasalazine and PhCL28A inhibit the formation of ethanol- and phenylbutazone-induced rat gastric ulcers: lack of involvement of endogenous prostaglandins? Br J Pharmacol (1988) 0.97
Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system. J Pharm Pharmacol (1976) 0.97
Serotonin and 5-hydroxyindoleacetic acid in discrete areas of the brainstem of suicide victims and control patients. Adv Biochem Psychopharmacol (1974) 0.96
Spontaneous and drug-induced changes of cerebral dopamine turnover during postnatal development of rats. Brain Res (1973) 0.96
L-glutamic acid decarboxylase in Parkinson's disease: effect of L-dopa therapy. Nature (1973) 0.95
Distribution and metabolism of L-3-O-methyldopa in rats. Br J Pharmacol (1970) 0.95
Chronic antidepressants and GABA "B" receptors: a GABA hypothesis of antidepressant drug action. Life Sci (1984) 0.95
GABA involvement in neuroleptic-induced catalepsy. J Pharm Pharmacol (1978) 0.94
gamma-Aminobutyric acid (GABA) receptor stimulation. II. Specificity of progabide (SL 76002) and SL 75102 for the GABA receptor. J Pharmacol Exp Ther (1982) 0.93
Drug-induced changes of extracerebral dopa metabolism in man. Arch Neurol (1969) 0.93
Accumulation of dopamine in the parenchyma after decarboxylase inhibition in the capillaries of brain. Experientia (1968) 0.92
Familial fatal Parkinsonism with alveolar hypoventilation and mental depression. Ann Neurol (1979) 0.91
Effects of clozapine on cerebral catecholaminergic neurone systems. Br J Pharmacol (1972) 0.91
Neurotransmitter interactions related to central dopamine neurons. Essays Neurochem Neuropharmacol (1978) 0.91
Pharmacological and behavioral profile of alpidem as an anxiolytic. Pharmacopsychiatry (1990) 0.91
Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation. J Neurol Sci (1973) 0.91
CNS compensation to dopamine neuron loss in Parkinson's disease. Adv Exp Med Biol (1977) 0.90
Enhancement of cerebral noradrenaline turnover by thyrotropin-releasing hormone. Nature (1974) 0.90
Aralkylamines with different effects on the metabolism of aromatic monoamines. J Pharmacol Exp Ther (1966) 0.89
Effect of monoamine liberators on the metabolism of 5-hydroxytryptamine in blood platelets. Biochem Pharmacol (1965) 0.89
Evidence for an intrastriatal GABA-ergic influence on dopamine neurones of the cat. Neuropharmacology (1977) 0.89
Formation of 5-hydroxytryptophol by blood platelets after thrombin and reserpine. Experientia (1965) 0.89
gamma-Aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas. J Pharmacol Exp Ther (1982) 0.88
gamma-Aminobutyric acid (GABA) receptor stimulation. I. Neuropharmacological profiles of progabide (SL 76002) and SL 75102, with emphasis on their anticonvulsant spectra. J Pharmacol Exp Ther (1982) 0.88
Distribution of choline acetyltransferase and glutamate decarboxylase within the substantia nigra and in other brain regions from control and Parkinsonian patients. J Neurochem (1975) 0.87
Occurrence and distribution of aromatic L-amino acid (L-DOPA) decarboxylase in the human brain. J Neurochem (1972) 0.87
On the origin of homovanillic acid in the cerebrospinal fluid. Experientia (1966) 0.87
The metabolic pathways of L-3-O-methyldopa. J Pharmacol Exp Ther (1972) 0.87
gamma-Aminobutyric acid (GABA) receptor stimulation. IV. Effect of progabide (SL 76002) and other GABAergic agents on acetylcholine turnover in rat brain areas. J Pharmacol Exp Ther (1982) 0.87
GABA receptor agonists: pharmacological spectrum and therapeutic actions. Med Res Rev (1985) 0.85
The gabaergic hypothesis of depression. Prog Neuropsychopharmacol Biol Psychiatry (1989) 0.85
The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacol Biochem Behav (1983) 0.85
Enhanced striatal acetylcholine release by chlorpromazine and its reversal by apomorphine. Brain Res (1973) 0.84
New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem (1980) 0.84
Acetylcholine release within the cat striatum during the sleep-wakefulness cycle. Nature (1973) 0.84
Two types of monoamine liberation by chlorinated aralkylamines. Life Sci (1965) 0.83
An analysis of [3H]gamma-aminobutyric acid (GABA) binding in the human brain. Brain Res (1979) 0.83
Enhancement of tyrosine hydroxylation within the brain by chlorpromazine. Experientia (1969) 0.83
Temperature dependence of the passive in- and outflow of 5-hydroxytryptamine in blood platelets. Biochem Pharmacol (1966) 0.83
Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile. J Pharmacol Exp Ther (1987) 0.82
Increase of 3-methoxy-4-hydroxyphenylethylene glycol in rat brain by neuroleptic drugs. Eur J Pharmacol (1973) 0.82
GABA and affective disorders. Med Biol (1987) 0.82
[GABAergic theory of epilepsy]. Rev Prat (1986) 0.81
Selectivity for omega-receptor subtypes as a strategy for the development of anxiolytic drugs. Pharmacopsychiatry (1990) 0.81
The use of the push-pull cannula to estimate the dynamics of acetylcholine and catecholamines within various brain areas. Neuropharmacology (1976) 0.81
Fengabine, a novel antidepressant GABAergic agent. II. Effect on cerebral noradrenergic, serotonergic and GABAergic transmission in the rat. J Pharmacol Exp Ther (1987) 0.81
[The capillary enzyme barrier for DOPA at the level of some brain stem nuclei in the rat]. Experientia (1970) 0.81
Cortical modulation of striatal function. Brain Res (1982) 0.81
Brain capillaries as a source of homovanillic acid in cerebrospinal fluid. Brain Res (1971) 0.81
Dopaminergic inhibition of striatal cholinergic neurons: synergistic blocking action of gamma-butyrolactone and neuroleptic drugs. Naunyn Schmiedebergs Arch Pharmacol (1974) 0.81
Formation of monoamines from various amino acids in the brain after inhibition of extracerebral decarboxylase. Biochem Pharmacol (1971) 0.81
Comparative investigation of inhibitors of extracerebral dopa decarboxylase in man and rats. J Pharm Pharmacol (1972) 0.80
[3H]GABA binding in brains from Huntington's chorea patients: altered regulation by phospholipids? Science (1979) 0.80
Effect of neuroleptics on endogenous norepinephrine in rat brain. Neuropharmacology (1973) 0.80
Effects of the GABA receptor agonist, progabide, upon local cerebral glucose utilization. Brain Res (1987) 0.80
Catecholamine and octopamine concentrations in brains of patients with Reye syndrome. Neurology (1977) 0.80
Degeneration and regeneration of adrenergic nerves in mesenteric blood vessels, iris and atrium of the rat after 6-hydroxydopamine injection. J Neurocytol (1975) 0.79
Dopa-induced locomotor stimulation after inhibition of extracerebral decarboxylase. J Pharm Pharmacol (1969) 0.79
Modulation by GABA of cholinergic transmission in the striatum. Brain Res (1980) 0.79
Effect of clonidine on utilization and potassium-evoked release of adrenaline in rat brain areas. Brain Res (1979) 0.79
Influence of GABA-agonists and antagonists on neuroleptic-induced catalepsy in rats. Life Sci (1978) 0.79
Evidence that clomethiazole interacts with the macromolecular GABA A-receptor complex in the central nervous system and in the anterior pituitary gland. Naunyn Schmiedebergs Arch Pharmacol (1989) 0.79
Neuropharmacological spectrum of muscimol. Life Sci (1979) 0.78